Targeting SSTR2 in NB was previously demonstrated clinically using 68Ga-, 177Lu- and 90Y-labeled DOTA-TATE [16, 18, 20], although a recent study failed to show a benefit of [177Lu]Lu-DOTA-TATE in NB patients, possibly due to the relatively low administered dose in this study [19]. The gene discussed is SSTR2; the disease is neuroblastoma.